Mesoblast Ramps Up Ryoncil Sales, Advances Late-Stage Cell Therapy Pipeline

Mesoblast Limited ( (AU:MSB) ) has shared an update.

Mesoblast reported quarterly net revenues of US$30.3 million from Ryoncil, with gross sales of US$35.3 million, bringing first-year launch revenue close to US$100 million and cutting net operating cash spend to US$4.1 million, supported by US$122 million in cash on hand. The strong sales momentum and tighter cost control underscore improving financial resilience as the company scales its first commercial MSC therapy.

Operationally, Mesoblast reached its patient recruitment target in a pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain and secured regulatory clearances to advance label extension studies for Ryoncil in adult SR-aGvHD and a registrational trial in Duchenne muscular dystrophy. The acquisition of an exclusive CAR technology platform for precision-enhanced MSCs positions Mesoblast to expand into ulcerative colitis, Crohn’s disease and B cell autoimmune disorders, reinforcing its leadership in allogeneic cell therapy and broadening potential revenue streams.

The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.

More about Mesoblast Limited

Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines targeting severe and life-threatening inflammatory conditions. Its lead product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and the company is advancing additional indications in inflammatory diseases, heart failure and chronic low back pain through its remestemcel-L and rexlemestrocel-L platforms.

Average Trading Volume: 3,824,857

Technical Sentiment Signal: Hold

Current Market Cap: A$2.77B

See more insights into MSB stock on TipRanks’ Stock Analysis page.